Egis Gyogyszergyar Rt.

Egis Gyogyszergyar Nyrt

Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Les Laboratoires Servier

Egis Hyogyszergyar Nyrt.

Egis Gyogyszergyar Zrt.

József Barkóczy

Gyula Simig

György Lévay

István Gacsályi

Péter Kótay Nagy

Tibor Mezei

Balázs Volk

Gábor Szénási

András Egyed

László Gábor Hársing

Katalin Pallagi

Gábor Gigler

Csilla Leveleki

Márta Porcs-Makkay

Kálmán Nagy

Krisztina Móricz

János Wellmann

László Hársing

Nóra Sziray

Rita Kapillerné Dezsöfi

Bernadett Martonné Markó

István Ling

Michael Spedding

Zoltán Greff

László Szlávik

Gábor Németh

Adrienn Keszthelyi

Éva Schmidt

Zsuzsanna Szent-Királlyi

Tamás Gregor

Gyula Lukács

Györgyi Vereczkeyné Donáth

Enikó Molnár

Tibor Szabó

János Szulágyi

Bálint Nyulasi

Ferenc Antoni

Gyuláné Körtvélyessy

András Mravik

Mátyás Milen

Judit Broda

Miklós Végh

Angéla Pandur

Éva Pécsi

László Pongó

Hajnalka Kompagne

Anikó Miklósné Kovács

Judit Ráczné Bajnógel

Géza Szabó

Ferenc Bertha

Zoltán Rátkai

Endréné Flórian

Béla Farkas

György Ruzsics

Enikö Molnár

József Debreczeni

István Gascályi

Mária Vajjon

György Krasznai

János Pethö

Zsuzsa Szent-Királlyi

Gábor Szenasi

Imre KÖHEGYI

Péter Kiricsi

Elemér Fogassy

Ildikó Nagyné Gyönös

István Gacsalyi

József Schindler

József Fetter

Balázs Molnar

Bernadett Markó

Imre KIRÁLY

Laszló PongÓ

Mária KOVÁCS

Tibor SzabÓ

Maria TÓTHNÉ Lauritz

Ferenc Lóránt Bartha

Mária Júlia TÁBORINE TÓTH

András Boza

László József HEGEDÜS

Györgyi KOVÁNYINÉ Lax

András DancsÓ

Mária TÓTHNÉ Lauritz

ÉVa Sipos

Balázs Havasi

Katalin Nagy

The object of the present invention is a process for preparing the 2-acetoxi-5-(2-fluor-&#x3b1;-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-thieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts from crystalline 5-trityl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof.

Process for preparing pharmaceutical compounds and intermediate compounds

Compounds of formula (I): wherein: Medicinal products containing the same which are useful in the treatment or prevention of psychiatric and neurological disorders characterized by cognitive deficits.

Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them

The invention relates to a process for the preparation of cyclopropyl benzyl ketone compounds of formula (II) wherein Rrepresents fluorine or chlorine atom or Calkoxy group, by the reaction of a Grignard reagent, obtained from the reaction of compound of formula (V), wherein X represents chlorine or fluorine atom, with the compound of formula (IV), wherein Rrepresents Calkyl group, having a straight or branched chain. The process can be applied preferably on industrial scale. Compound of formula (II), wherein R represents a fluorine atom in position 2 is an intermediate of the preparation process of prasugrel, which is a platelet inhibitor used in the therapy. 

Process for the preparation of pharmaceutical intermediates

The present invention relates to new crystalline forms I, II and III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine hydrochloride, a process for the preparation thereof and pharmaceutical compositions containing the same. Said new polymorphic forms are useful as active ingredients for the treatment of psychotic conditions.

Polymorphs of olanzapine hydrochloride

The present invention is concerned with new indol-2-one derivatives of Formula (I), which have favorable activity profile for the prophylaxis and treatment of disorders in the central nervous or in the cadiovascular system. 

Piperazine derivatives of alkyl oxindoles

The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I), wherein Rstands for hydrogen, halogen, alkyl having 1-7 carbon atom(s) or sulfonamido; Rrepresents hydrogen or halogen; Rdenotes hydrogen, alkyl having 1-7 carbon atom(s) optionally carrying an aryl substituent or aryl optionally carrying one or two halogen substituent(s); Rstands for alkyl having 1-7 carbon atom(s); Rrepresents a group of the general Formula (II a) or (II b), wherein Q and W each represents nitrogen or CH; R, Rand Reach stands for hydrogen, halogen, trifluoromethyl, alkyl or alkoxy having 1-7 carbon atom(s), or Rand Rtogether represent ethylenedioxy; m is 0, 1, or 2; a is a single, double or triple bond; n is 0, 1 or 2; and pharmaceutically acceptable acid addition salts thereof which are useful in the treatment or prophylaxis of diseases of the central nervous system, the gastrointestinal system and the cardiovascular system. 

Piperazine derivatives of dialkyl oxindoles

The present invention relates to a new method of preparation of the polymorph form 1 of methyl (S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate of the formula (I) 

Process for the preparation of amorphous form of a platelet aggregation inhibitor drug

The invention refers to novel 2,3-benzodiazepine derivatives of formula (I) and pharmaceutical compositions containing the same as the active ingredient. The novel compounds antipasmodic, muscle relaxant and neuroprotective activities. In formula I; X represents a hydrogen atom, a chloro atom or a methoxy group; Y stands for a hydrogen atom or a halo atom; Z means a methyl group or a chloro atom; R is a Calkyl group or a group of the formula &#x2014;NRR, wherein Rand Rrepresent, independently, a hydrogen atom, a Calkyl group, a Calkoxy group or a Ccycloalkyl group. 

2, 3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient

The invention relates to new piperidinyl-alkylamino-pyridazinone derivatives of the general Formula (I) (wherein R is hydrogen or C-alkyl; one of X and Y stands for hydrogen and the other represents a group of the general Formula (II) Hal stands for halogen; and n is 1 or 2) and pharmaceutically acceptable acid addition salts thereof a process for the preparation thereof and pharmaceutical compositions comprising said compounds. The compounds of the general Formula I exhibit anxiolytic effect and are useful in the treatment of anxiety 

Piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds

The invention refers to novel 2H-pyridazine-3-one derivatives of the formula I, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient. The novel compounds possess neuroleptic effect and can be used, primarily, for the treatment of schizophrenia. In formula I, R stands for a hydrogen atom or a C, alkyl group, X and Y represent, independently, a hydrogen atom, a halogen atom or a group of the formula II, with the proviso that one of X and Y means always a group of the formula II, and then the other one stands for a hydrogen atom or a halogen atom, wherein in formula II n has a value of 1 or 2. 

2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient

The invention relates to substituted alkylaminopyridazinone derivatives of the general Formula (I), (wherein Ris hydrogen or alkyl having 1-4 carbon atoms; one of X and Y stands for hydrogen or halogen and the other represents a group of the general Formula (II), Ris hydrogen or alkyl having 1-4 carbon atoms; n is 1, 2 or 3; Rstands for hydrogen, alkyl having 1-4 carbon atoms or aryl-(Calkyl); Z stands for oxygen; or Rand Z together with the groups placed between them form a piperazine ring; and Rstands for hydrogen, halogen, trifluoromethyl or alkoxy having 1-4 carbon atoms) and pharmaceutically acceptable acid addition salts thereof. The invention compounds are useful in the treatment of anxiolytic conditions and cognitive disorders.

Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same

Growing community of inventors

Budapest, Hungary

József Barkóczy